| Literature DB >> 29857504 |
Silke Nolte-Buchholtz1, Boris Zernikow2,3, Julia Wager4,5.
Abstract
In Germany, every child with a life-limiting condition suffering from symptoms that cannot sufficiently be controlled is eligible by law for specialized pediatric palliative home care (SPPHC). It is the aim of this study to describe the demographic and clinical characteristics of children referred to SPPHC and to compare patients with cancer and non-cancer conditions. The prospective multicenter study includes data on 75 children (median age 7.7 years, 50.7% male). The majority had non-cancer conditions (72%). The most common symptoms were cognitive impairment, somatic pain, impairment in communication or swallowing difficulties. Swallowing difficulties, seizures, and spasticity occurred significantly more often in non-cancer patients (p < 0.01). Cancer patients received antiemetics significantly more often (permanent and on demand) than non-cancer patients (p < 0.01). Significantly more non-cancer patients had some type of feeding tube (57.3%) or received oxygen (33.3%) (p < 0.01). Central venous catheters had been fitted in 20% of the patients, mostly in cancer patients (p < 0.001). Tracheostomy tubes (9.3%) or ventilation (14.7%) were only used in non-cancer patients. In conclusion, patients referred to SPPHC are a diverse cohort with complex conditions including a large range of neurologically originating symptoms. The care of pediatric palliative care patients with cancer is different to the care of non-cancer patients.Entities:
Keywords: cancer; home care; non-cancer; palliative care; pediatrics
Year: 2018 PMID: 29857504 PMCID: PMC6028915 DOI: 10.3390/children5060066
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Diagnoses of patients in the cohort.
| Diagnoses ( |
| % |
|---|---|---|
|
| 21 | 28.1 |
| Solid tumor | 11 | 14.7 |
| Brain tumor | 8 | 10.7 |
| Leukemia | 2 | 2.7 |
|
| 54 | 71.9 |
| Neuromuscular | 28 | 37.0 |
| Neurodegenerative | 9 | 12.0 |
| Chromosomal Aberration | 6 | 8.0 |
| Cardiovascular | 6 | 8.0 |
| Respiratory | 1 | 1.3 |
| Gastrointestinal | 1 | 1.3 |
| Other a | 3 | 4.0 |
a VACTERL association (vertebral defects, anal atresia, cardiac defects, tracheo-esophageal fistula, renal anomalies, and limb abnormalities), agenesis of the pons, Lennox encephalopathy.
Patient characteristics.
| Characteristics | Total Patients | Cancer Patients | Non-Cancer Patients | Statistics | |||||
|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| Chi-Square | ||
|
| 1 | 0.006 | 1.000 | ||||||
| Female | 34 | 49.3 | 10 | 50.0 | 24 | 49.0 | |||
| Male | 35 | 50.7 | 10 | 50.0 | 25 | 51.0 | |||
|
| 4 | 7.45 | 0.114 | ||||||
| 0–1 month | 1 | 1.3 | 0 | 0.0 | 1 | 1.9 | |||
| 2–11 month | 15 | 20.0 | 1 | 4.8 | 14 | 25.9 | |||
| 1–9 years | 27 | 36.0 | 8 | 38.1 | 19 | 35.2 | |||
| 10–18 years | 22 | 29.3 | 10 | 47.6 | 12 | 22.2 | |||
| Older than 18 years | 10 | 13.3 | 2 | 9.5 | 8 | 14.8 | |||
|
| 2 | 0.42 | 0.810 | ||||||
| With migration background 1 | 12 | 16.0 | 3 | 20.0 | 9 | 21.4 | |||
|
| 2 | 3.99 | 0.136 | ||||||
| With both parents | 53 | 70.7 | 17 | 81.0 | 36 | 66.6 | |||
| Only/mostly with mother | 13 | 17.3 | 4 | 19.0 | 9 | 16.7 | |||
| Other 2 | 9 | 12 | 0 | 0.0 | 9 | 16.7 | |||
|
| 2 | 3.01 | 0.222 | ||||||
| Siblings with LLC | 7 | 9.7 | 0 | 0.00 | 7 | 100.0 | |||
1 Definition [6]; 2 Includes grandmother, hospice for adults, hospice for children (n = 2), sheltered accommodation, five of nine patients are older than 18 years; LLC, life-limiting conditions; df, degrees of freedom.
Care goals.
| Characteristics | Total Patients ( | Cancer Patients ( | Non-Cancer Patients ( | ||||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Counsel a | 69 | 93.2 | 19 | 90.5 | 50 | 94.3 | 0.618 |
| Symptom management | 66 | 89.2 | 20 | 95.2 | 46 | 86.8 | 0.427 |
| Empowerment b | 53 | 71.6 | 13 | 61.9 | 40 | 75.5 | 0.264 |
| Communication about symptoms/course of disease | 51 | 68.9 | 16 | 76.2 | 35 | 66 | 0.578 |
| Decision-making support | 48 | 64.9 | 16 | 76.2 | 32 | 60.4 | 0.282 |
| Transition to home | 15 | 20.3 | 6 | 28.6 | 9 | 17.0 | 0.388 |
| Logistic and coordination of care | 34 | 45.9 | 10 | 47.6 | 24 | 45.3 | 1.000 |
| Discuss DNAR order | 34 | 45.9 | 11 | 52.4 | 23 | 43.4 | 0.606 |
| Consultation of further provider/carer | 25 | 33.8 | 8 | 38.1 | 17 | 32.1 | 0.786 |
a Counseling of the patient (n = 24), the family (n = 62), the pediatrician (n = 34), the nursing service (n = 23), the health care service provider (n = 6). Counseling of the patient and the nursing service is significant between cancer and non-cancer group (<0.001); b Empowerment of the patient (n = 13), the family (n = 49), the pediatrician (n = 7), the nursing service (n = 17). Empowerment of the patient is significant between cancer and non-cancer group (p < 0.001); c Fisher-test; DNAR, do not attempt resuscitation.
Figure 1Symptom prevalence. * Other: hypothermia, dry mouth, edema, itching.
Symptoms in cancer and non-cancer patients.
| Total Patients | Cancer Patients | Non-Cancer Patients | ||
|---|---|---|---|---|
| Impairment in communication | 46 (63.0) | 9 (42.9) | 37 (71.2) | 0.033 |
| Swallowing difficulties | 39 (52.7) | 5 (23.8) | 34 (66.0) | 0.002 * |
| Somatic pain | 39 (53.4) | 13 (61.9) | 26 (50.0) | 0.441 |
| Cognitive impairment | 38 (52.1) | 6 (28.6) | 32 (61.5) | 0.019 |
| Seizures | 33 (45.8) | 2 (9.5) | 31 (60.8) | <0.001 * |
| Sleep disturbance | 33 (45.2) | 12 (57.1) | 21 (40.4) | 0.207 |
| Loss of appetite | 32 (43.8) | 12 (57.1) | 20 (38.5) | 0.194 |
| Constipation | 30 (41.1) | 7 (33.3) | 23 (44.2) | 0.441 |
| Dyspnea | 30 (41.1) | 4 (19.0) | 26 (50.0) | 0.019 |
| Anxiety | 27 (38.0) | 13 (65.0) | 14 (27.5) | 0.006 |
| Paralysis | 25 (34.2) | 7 (33.3) | 18 (34.6) | 1.000 |
| Spasticity | 25 (34.2) | 0 (0.0) | 25 (48.1) | <0.001 * |
| Weight loss | 22 (30.1) | 8 (38.1) | 14 (26.9) | 0.403 |
| Vomiting | 21 (28.8) | 8 (38.1) | 13 (25.0) | 0.271 |
| Nausea | 20 (27.4) | 8 (38.1) | 12 (23.1) | 0.248 |
| Cough | 18 (24.7) | 3 (14.3) | 15 (28.8) | 0.241 |
| Hypersalivation | 17 (23.3) | 1 (4.8) | 16 (30.8) | 0.017 |
| Neuropathic pain | 16 (22.2) | 3 (14.3) | 13 (25.5) | 0.365 |
| Myoclonia | 15 (20.3) | 1 (4.8) | 14 (26.4) | 0.053 |
| Infection | 14 (19.2) | 4 (19.0) | 10 (19.2) | 1.000 |
| Sweating | 14 (19.2) | 1 (4.8) | 13 (25.0) | 0.092 |
| Fatigue | 13 (17.8) | 8 (38.1) | 5 (9.6) | 0.007 |
| Visceral pain | 11 (15.5) | 4 (19.0) | 7 (14.0) | 0.721 |
| Wound | 11 (15.1) | 4 (19.0) | 7 (13.5) | 0.719 |
| Urinary retention | 9 (12.3) | 4 (19.0) | 5 (9.6) | 0.269 |
| Fever | 9 (12.2) | 5 (23.8) | 4 (7.5) | 0.107 |
| Diarrhea | 8 (11.0) | 4 (19.0) | 4 (7.7) | 0.216 |
| Other b | 16 | 5 | 11 |
a Fisher’s exact test; b Other: hypothermia, dry mouth, edema, itching; * result is significant after Bonferroni-Holm correction.
Figure 2Symptom burden in patients with cancer and non-cancer condition.
Clinical characteristics of cancer and non-cancer patients.
| Characteristics | All Patients | Cancer Patients | Non-Cancer Patients | ||||
|---|---|---|---|---|---|---|---|
| Mean (SD) | Range | Mean (SD) | Range | Mean (SD) | Range | ||
|
| 3.80 (2.48) | 0–12 | 3.33 (2.13) | 0–7 | 4.00 (2.61) | 0–12 | 0.305 |
|
| 2.44 (2.02) | 0–12 | 2.24 (1.58) | 0–7 | 2.52 (2.19) | 0–12 | 0.595 |
|
|
|
|
|
|
|
|
|
| 75 | 100 | 21 | 100 | 54 | 100 | ||
|
| 43 | 57.3 | 1 | 4.8 | 42 | 77.8 | <0.001 * |
| Nasogastric tube | 15 | 20.0 | 1 | 4.8 | 14 | 25.9 | |
| Gastro-or jejunost. tube | 29 | 38.7 | 0 | 0.0 | 29 | 53.7 | |
|
| 15 | 20.0 | 11 | 52.4 | 4 | 7.4 | <0.001 * |
|
| 7 | 9.3 | 0 | 0.0 | 7 | 13.0 | 0.180 |
|
| 11 | 14.7 | 0 | 0.0 | 11 | 20.4 | 0.028 |
| Invasive ventilation | 6 | 8.0 | 0 | 0.0 | 6 | 11.1 | |
| Noninvasive ventilation | 5 | 6.7 | 0 | 0.0 | 5 | 9.3 | |
|
| 25 | 33.3 | 1 | 4.8 | 24 | 44.4 | 0.003 * |
|
| 3 | 4.0 | 2 | 9.5 | 1 | 1.9 | 0.188 |
|
| 51 | 68.0 | 9 | 42.9 | 42 | 77.8 | 0.008 * |
| Physiotherapy | 49 | 65.3 | 8 | 38.1 | 41 | 75.9 | |
| Occupational therapy | 18 | 24.0 | 2 | 9.5 | 16 | 29.6 | |
| Speech therapy | 10 | 13.3 | 0 | 0.0 | 10 | 18.5 | |
| Music therapy | 5 | 6.7 | 0 | 0.0 | 5 | 9.3 | |
| Homeopathy | 5 | 6.7 | 1 | 4.8 | 4 | 7.4 | |
| Art therapy | 1 | 1.3 | 0 | 0.0 | 1 | 1.9 | |
| Acupuncture | 0 | 0.0 | |||||
at-Test; b Fisher’s exact test; * result is significant after Bonferroni-Holm correction; SD, standard deviation; VP/VA, ventriculoperitoneal/ventriculoatrial.
Medication of cancer and non-cancer patients.
| All Patients | Cancer Patients | Non-Cancer Patients | |||||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Permanent medication | 70 | 100 | 21 | 100 | 49 | 100 | |
| Antacids | 28 | 40 | 9 | 42.9 | 19 | 38.8 | 0.794 |
| Anticonvulsants | 25 | 35.7 | 4 | 19.0 | 21 | 42.9 | 0.064 |
| Laxatives | 23 | 32.9 | 6 | 28.6 | 17 | 34.7 | 0.783 |
| Immunotherapeutic | 18 | 25.7 | 5 | 23.8 | 13 | 26.2 | 1.000 |
| Vitamin | 17 | 24.3 | 1 | 4.8 | 16 | 32.7 | 0.014 |
| Strong Opioid | 15 | 21.4 | 8 | 38.1 | 7 | 14.3 | 0.053 |
| Antibiotics | 15 | 21.4 | 6 | 28.6 | 9 | 18.4 | 0.356 |
| Broncholytics | 12 | 17.1 | 1 | 4.8 | 11 | 22.4 | 0.092 |
| Non-Opioid | 11 | 15.7 | 5 | 23.8 | 6 | 12.2 | 0.286 |
| Muscle Relaxants | 11 | 15.7 | 0 | 0.0 | 11 | 22.4 | 0.027 |
| Antiemetics | 7 | 10.0 | 6 | 28.6 | 1 | 2.0 | 0.002 * |
| Diuretics | 7 | 10.0 | 0 | 0.0 | 7 | 14.3 | 0.094 |
| Sedatives | 4 | 5.7 | 1 | 4.8 | 3 | 6.1 | 1.000 |
| Mild Opioids | 3 | 4.3 | 1 | 4.8 | 2 | 4.1 | 1.000 |
| Antidepressives | 1 | 1.4 | 1 | 4.8 | 0 | 0.0 | 0.300 |
| On demand medication | 70 | 100 | 21 | 100 | 49 | 100 | |
| Non-Opioid | 27 | 38.6 | 7 | 33.3 | 20 | 40.8 | 0.603 |
| Sedatives | 24 | 34.3 | 5 | 23.8 | 19 | 38.8 | 0.280 |
| Anticonvulsants | 24 | 33.8 | 4 | 19.0 | 20 | 40.0 | 0.106 |
| Strong Opioid | 22 | 31.0 | 11 | 52.4 | 11 | 22.0 | 0.023 |
| Laxatives | 16 | 22.9 | 4 | 19.0 | 12 | 24.5 | 0.761 |
| Antiemetics | 15 | 21.4 | 10 | 47.6 | 5 | 10.2 | 0.001 * |
| Mild Opioid | 4 | 5.7 | 1 | 4.8 | 3 | 6.1 | 1.000 |
a Chi-square test; * result is significant after Bonferroni-Holm correction.